DILIsym Services

A SIMULATIONS PLUS COMPANY

www.dilisym.com

(NASDAQ: SLP)

What's new in DILIsym® 8A?

- **NEW** Exemplar Compounds
  - 10 New compounds, including GSK compounds and valproate
- **NEW** Cholestatic liver injury mechanism
- **NEW** Oxidative stress (ROS) NRF2 adaptation response framework
- **NEW** Human SimPops with variability in bilirubin processing pathways
- **NEW** Liver injury biomarker GLDH
- Supported by the DILI-sim Initiative consortium and licensed by the FDA

DILIsym is Quantitative Systems Toxicology (QST) software capable of **predicting** and **explaining** Drug-Induced Liver Injury (DILI)



DILIsym includes multiple interacting sub-models such as:

- Bile acid homeostasis and disruption by transporter inhibition
- Mitochondrial function and induced dysfunction
- Steatosis and lipotoxicity
- Inflammation
- Oxidative stress
- Hepatocyte apoptosis, necrosis, and proliferation
- Actively secreted as well as cell leakage biomarkers
- Compatible with GastroPlus™ and also includes built-in PBPK capability

Take your DILI research further...

- Utilizes compound-specific *in vitro* data to enable predictions
- Humans, rats, mice and dogs included
- SimPops™ incorporate inter-individual physiological variability
- User-friendly interface for *in silico* experiments and visualization of results

DILIsym Services:
+1-919-558-1323
licensing@dilisym.com

Simulations Plus:
+1-661-723-7723
info@simulations-plus.com

Cognigen:
+1-716-633-3463
info@cognigencorp.com

Rev. 12/13/18